UniQure's trailblazing gene therapy has met its end. After struggling for years with the ultraexpensive Glybera, the company is calling it quits on the…

It was destined to happen: Amgen has sued Sanofi and Regeneron, claiming their newly approved Dupixent infringes one of its antibody patents.

Biogen's Spinraza raised eyebrows for a $750,000 first-year price, but rare disease medications are expensive, period. Check out this list.

After years of pumping up its wellness content, Condé Nast has launched a new pharma-focused division to spur its reader-targeting powers and drive more custom…

What’s the poop? A new emoji keyboard from Synergy Pharmaceuticals, that's what, as the drugmaker launches its latest chronic idiopathic constipation…

J&J missed analyst expectations on pharma and consumer health sales in the first quarter as some of its stalwart performers shrank instead of grew.

Bristol-Myers Squibb pulled the rug out from under Opdivo TV ad spending in March after battling Merck’s rival med Keytruda near the top of the February charts.

To partner or not to partner on a new drug launch? Of all the decisions emerging biopharma companies have to make, that's among the most important.

Marketing